SCHEMBL13250547

SCHEMBL13250547

Clc1cccc(C(c2ccc(CN3CCCNCc4cccc(c4)CNCCC3)cc2)c2ccc(CN3CCCNCc4cccc(c4)CNCCC3)cc2)c1

nearest known ligand 0.50

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ CXCR4 P61073 11/20 0.50
▸ MEN1 O00255 1/20 0.43
▸ CHRM2 P08172 1/20 0.43
▸ CHRM1 P11229 1/20 0.43
▸ ADRA2C P18825 1/20 0.43
▸ CCR2 P41597 1/20 0.43
▸ CXCL12 P48061 1/20 0.43
▸ BLM P54132 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ TDP1 Q9NUW8 1/20 0.43
▸ HRH3 Q9Y5N1 1/20 0.43
▸ SIGMAR1 Q99720 1/20 0.40
▸ SLC6A2 P23975 3/20 0.39
▸ SLC6A4 P31645 3/20 0.39
▸ SLC6A3 Q01959 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13250528 0.93 CXCR4 (0.47) CXCR4MEN1CHRM2CHRM1ADRA2C
SCHEMBL13250543 0.91 CXCR4 (0.50) CXCR4MEN1CHRM2CHRM1ADRA2C
SCHEMBL13250551 0.87 CXCR4 (0.63) CXCR4MEN1CHRM2CHRM1ADRA2C
SCHEMBL13250546 0.86 CXCR4 (0.48) CXCR4MEN1CHRM2CHRM1ADRA2C
SCHEMBL13250545 0.86 CXCR4 (0.48) CXCR4MEN1CHRM2CHRM1ADRA2C
SCHEMBL13250544 0.86 CXCR4 (0.55) CXCR4MEN1CHRM2CHRM1ADRA2C
SCHEMBL13250513 0.86 CXCR4 (0.62) CXCR4MEN1CHRM2CHRM1ADRA2C
SCHEMBL13447599 0.85 CXCR4 (0.52) CXCR4MEN1CHRM2CHRM1ADRA2C
SCHEMBL13250519 0.85 CXCR4 (0.43) CXCR4MEN1CHRM2CHRM1ADRA2C
SCHEMBL13250522 0.83 CXCR4 (0.46) CXCR4MEN1CHRM2CHRM1ADRA2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8420626-B2 Arene connected polyamine macrocyclic derivatives, preparation methods and pharmaceutical uses thereof BEIJING MOLECULE SCIENCE AND TECHNOLOGY CO., LTD. (CN) 2013-04-16 — — US disclosed
US-8420626-B2 Arene connected polyamine macrocyclic derivatives, preparation methods and pharmaceutical uses thereof BEIJING MOLECULE SCIENCE AND TECHNOLOGY CO., LTD. (CN) 2013-04-16 — — US disclosed
US-20100179116-A1 Arene Connected Polyamine Macrocyclic Derivatives, Preparation Methods and Pharmaceutical Uses Thereof BEIJING MOLECULE SCIENCE AND TECHNOLOGY CO., LTD. (CN) 2010-07-15 — — US disclosed
US-20100179116-A1 Arene Connected Polyamine Macrocyclic Derivatives, Preparation Methods and Pharmaceutical Uses Thereof BEIJING MOLECULE SCIENCE AND TECHNOLOGY CO., LTD. (CN) 2010-07-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100179116-A1 Arene Connected Polyamine Macrocyclic Derivatives, Preparation Methods and Pharmaceutical Uses Thereof SRM, SP1, SMS CXCR4 555/4885MEN1 657/4885CHRM2 2669/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback